BridgeBio Oncology Therapeutics (BBOT) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 16, 2026, with virtual participation available for shareholders.

• Shareholders are encouraged to review proxy materials and annual report before voting.

Voting matters and shareholder proposals

• Election of two Class I directors, Frank McCormick and Peter Lebowitz, to serve until the 2029 annual meeting.

• Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Provision to transact any other business properly brought before the meeting or its adjournment.

Board of directors and corporate governance

• Board recommends voting in favor of both director nominees and the auditor ratification.